Source comparison
Side-by-Side Comparison
Mechanism GHRH receptor agonist (synthetic analog) GHRH receptor agonist (natural GHRH 1-29) Evidence Grade B+ A- Half-Life ~8 days (with DAC); ~30 min (no DAC) ~10-20 minutes Route Subcutaneous injection Typical Dose 2 mg/week (DAC); 100 mcg 2-3x/day (no DAC)
This comparison does not assign a generated winner or score.
- Mechanism
- GHRH receptor agonist (synthetic analog)
- GHRH receptor agonist (natural GHRH 1-29)
- Evidence Grade
- B+
- A-
- Half-Life
- ~8 days (with DAC); ~30 min (no DAC)
- ~10-20 minutes
- Route
- Subcutaneous injection
- Typical Dose
- 2 mg/week (DAC); 100 mcg 2-3x/day (no DAC)
- 200 - 300 mcg before bed daily
- GH Release Pattern
- Sustained elevation (DAC); pulsatile (no DAC)
- Pulsatile (mimics natural secretion)
- Dosing Frequency
- 2-3x/week (DAC); daily (no DAC)
- Daily (typically before bed)
- Best For
- Sustained IGF-1 elevation, convenience
- Natural GH pulsatility, clinical-grade research
- FDA Status
- Not FDA-approved; research compound
- Previously FDA-approved (Geref); withdrawn 2008
- Cost (research grade)
- $$
- $